6 December 2023
Scientists Plead to Be Heard in Pesticide Debate: Exposure Linked to Risk of Developing Parkinson´s Disease Via Changes in Gut Microbiome
Amsterdam, the Netherlands – While the European Union has just renewed the approval of the use of herbicide glyphosate for another ten years, scientists issue a call to action to reduce or replace the use of agrochemicals.
9 November 2023
Sage Grows Research Portfolio by Acquiring IOS Press
Los Angeles, USA – Global independent academic publisher Sage has acquired IOS Press, an independent publisher founded in Amsterdam in 1987 that specializes in health, life, and computer sciences.
21 June 2023
Journal of Parkinson's Disease (JPD) Included in the Directory of Open Access Journals (DOAJ)
Amsterdam, The Netherlands - Editors-in-Chief Bas Bloem, MD, PhD, and Lorraine Kalia, MD, PhD, proudly announce Journal of Parkinson's Disease (JPD) has been accepted into the Directory of Open Access Journals (DOAJ). Being included in the DOAJ is a significant milestone as it means that JPD meets the rigorous standards of the DOAJ's evaluation process, which assesses the quality, openness, and transparency of open access journals.
23 March 2023
Adding Hope to the Therapeutic Mix Can Empower Persons with Parkinson's Disease
Healthcare professionals recommend adding “hopamine” as a prerequisite for personalized medicine. Based on the personal experiences of Marina Noordegraaf, a commentary published in the Journal of Parkinson’s Disease, proposes that adding “hopamine” to the therapeutic mix can contribute to the empowerment of persons with Parkinson's disease.
14 March 2023
Common Dry Cleaning Chemical Linked to Parkinson’s
Trichloroethylene (TCE), a chemical used for decaffeinating coffee and dry cleaning clothes, is linked to Parkinson's disease and known to cause cancer, miscarriages, and heart disease. Millions of people are exposed to TCE through contaminated groundwater and indoor air pollution, increasing their risk of developing Parkinson's.
16 December 2022
Journal of Parkinson’s Disease Awards 2022 Parkinson Prize
The Journal of Parkinson’s Disease and its publisher IOS Press are proud to announce the two articles that have won the 2022 Parkinson Prize. The authors of these articles are being recognized for their outstanding contributions to the advancement of Parkinson’s disease (PD) research. Recipients of the award are co-authors Thomas G. Beach, MD, PhD, FRCPC, Banner Sun Health Research Institute, and Charles H. Adler, MD, PhD, FAAN, Mayo Clinic Arizona (basic research article), and Simon Stott, PhD, Cure Parkinson’s (clinical research article).
1 December 2022
Growing Evidence for the Role of the Immune System in Parkinson’s Disease
Amsterdam, NL – In this special supplement to the Journal of Parkinson’s Disease, “The Immune System in Parkinson’s Disease,” experts highlight the latest research breakthroughs on the links between immune activation and neuroinflammation and Parkinson’s disease (PD) and discuss the challenges and novel therapeutic strategies targeting the immune system with the hope of reducing or reversing neurodegeneration.
18 October 2022
Journal of Parkinson’s Disease Transitioning to Gold Open Access in 2023
Amsterdam, October 20, 2022 – The Journal of Parkinson’s Disease (JPD), published by IOS Press, is pleased to announce that beginning in January 2023, JPD will transition to a Gold Open Access publication. This means that all articles published after that date will be immediately and permanently freely available online for readers to view, download, share, and reuse, and will enable authors to comply more easily with funder and institutional mandates.
17 June 2022
NWO Stevin Prize for Expert on Parkinson’s Disease Bas Bloem
Neurologist Bas Bloem, MD, PhD, FRCPE of Radboud University Medical Center receives this year’s Stevin Prize of the Dutch Research Council (NWO). The Stevin Award is the highest distinction in science for a researcher in the Netherlands who has achieved particular success in the area of knowledge utilization for society. Prof. Bloem is the recipient of this award for the social impact of his research into this common and debilitating disorder.
20 May 2022
Journal of Parkinson’s Disease Welcomes New Co-Editor-in-Chief Lorraine V. Kalia, MD, PhD, FRCPC
The Journal of Parkinson’s Disease is pleased to announce the appointment of new co-Editor-in-Chief, Lorraine V. Kalia, MD, PhD, FRCPC. Dr. Kalia joins co-Editor-in-Chief Bas Bloem, MD, PhD, FRCPE, and an eminent international editorial board, who are dedicated to the continuing success of the world’s leading journal in Parkinson’s research.
10 May 2022
Involving Patients with Parkinson’s Disease in Research Benefits Everyone
Although there is a growing trend to involve patients in clinical research, specific guiding principles for engaging individuals with Parkinson’s disease have not been established. The authors of this Call to Action emphasize the value of incorporating patient perspectives in clinical Parkinson’s disease studies and recommend how to include patient researchers effectively.
14 April 2022
Patrik Brundin Steps Down as JPD Co-Editor-in-Chief
We share the news that Patrik Brundin, MD, PhD has decided to step down as co-Editor-in-Chief (EIC), of the Journal of Parkinson’s Disease, with immediate effect, following his acceptance of a new position at Roche Pharmaceutical Research and Early Development. As a consequence of his moving away from academia, he now steps down from the journal to prevent any form of conflict of interests.
15 March 2022
Skin Biopsy Can Help Identify Patients with Parkinson’s Disease
The diagnosis of Parkinson’s disease (PD) is currently based on consensus clinical criteria. A novel study in JPD has found that the presence of neuronal deposits of the biomarker phosphorylated alpha-synuclein in the brain and the skin of patients with PD distinguishes them from individuals with symptoms of parkinsonism due to the accumulation of another protein, tau.
30 September 2021
Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and Care
Current knowledge about Parkinson’s disease (PD) does not reflect the diversity of people with the disease, according to The Michael J. Fox Foundation for Parkinson’s Research (MJFF). In a position paper published in JPD, MJFF research staff define four major areas of action to reduce health disparities and advance treatments for everyone with PD. It highlights steps the Foundation is taking in these areas, including a new program launched earlier this year.
23 September 2021
Pipeline of Cell and Gene Therapies Holds Promise for Repairing the Parkinsonian Brain
After several decades of pre-clinical development, cell- and gene-based therapies for Parkinson’s disease (PD) are now actively being explored. In this JPD special issue on “Repairing the Parkinsonian Brain,” experts highlight some of the current strategies being pursued to restore lost function and replace what is lost in the PD brain, with special emphasis on the challenges associated with translating advanced therapeutic approaches into pioneering clinical trials.
31 August 2021
New Study Sheds Light on Lives of People with Parkinson’s and their Carers
Results of a new European study published in JPD may help improve clinical practice by shedding light on the lives of people with PD and their carers, re-emphasizing the many challenges they face in everyday life.
30 August 2021
New Study Urges Neurologists to Advocate Vaccinations for Patients with Parkinson’s
Patients with Parkinson’s disease (PD) are at higher risk for vaccine-preventable respiratory illnesses. However, patients with advanced PD may have less access to vaccinations according to a new study published in the JPD. More than 30% of patients surveyed did not know whether their physicians
20 July 2021
Digital Technology Driving Tangible Advancements in Parkinson’s Disease Research and Clinical Care
Amsterdam, NL – Well over six million people globally have been diagnosed with Parkinson’s disease (PD), which has an enormous impact on the lives of patients, their families, and caregivers and is incurring mounting costs for society.
29 April 2021
International Task Force Determines Current Parkinson’s Disease Subtyping May Not Fit All Patients
28 April 2021
New Model May Explain the Mystery of Asymmetry in Parkinson’s Disease
Amsterdam, NL – Parkinson’s disease (PD) is characterized by slowness of movement and tremors, which often appear asymmetrically in patients.
26 April 2021
Which Parkinson’s Symptoms Do Patients Most Want to See Improved by Treatment?
Amsterdam, NL – Individuals with Parkinson’s disease (PD) face a wide range of symptoms and challenges.
A phase 3, 4-week, multicentre (130 loca-tions), randomized, double-blind, placebo-control-led, parallel-group study of TD-9855 in treating symptomatic neurogenic orthostatic hypotension in subjects with primary autonomic failure
A phase 3, 22-week, multi-center (61 locations), randomized withdrawal study of TD-9855 in treating symptomatic neurogenic orthostatic hypotension in subjects with primary autonomic failure
A phase 3, 182-week, open-label, multi-center (26 locations) extension study to investigate the safety and tolerability of TD-9855 in treating symptomatic neurogenic orthostatic hypotension (nOH) in subjects with primary autonomic failure
A phase 1 single- and multiple-ascending dose study to assess the safety, tolerability, and pharmacokinetics of BIIB094 administered intrathecally to adults with Parkinson’s disease (REASON).
A phase 1, randomized, placebo-controlled, double-blind study to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL151 in healthy volunteers.
A Randomized Double-blind Placebo-controlled Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson’s Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability, and Pharmacokinetics (PK) of IkT-148009 in Elderly Subjects
ANAVEX®2-73 Study in Parkinson’s Disease Dementia
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease
Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder
Ambroxol as a Treatment for Parkinson’s Disease Dementia
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson’s Disease (PD) or Dementia With Lewy Bodies (DLB)
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
Effect of Donepezil on Cognition in Parkinson’s Disease with Mild Cognitive Impairment (PD-MCI)
A Multicenter, Open-Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson’s Disease Dementia
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson’s Disease (TEMPO-1 TRIAL)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson’s Disease (TEMPO-2 Trial)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for PD in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3)
3 February 2021
COVID-19 Vaccination for Patients with Parkinson’s Disease Recommended
Patients with Parkinson’s disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine’s efficacy and safety in the specific context of PD and its symptomatic treatment. In a commentary just published in JPD, a set of experts addresses these concerns from an evidence-based perspective. Their conclusion is that COVID-19 vaccination with approved vaccines should be recommended to persons with PD, unless there is a specific contraindication.
26 January 2021
Over Half of Cannabis Users with Parkinson’s Disease Report Clinical Benefits
Amsterdam, NL – With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson’s disease (PD).